Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in ...

C-Further to advance its first two bespoke paediatric cancer therapeutics in collaboration with leading global academic and industry investigators Selected programmes to potentially address multiple ...

Ipsen is withdrawing tazemetostat from all markets following signals of secondary hematologic malignancies observed in SYMPHONY-1 evaluating tazemetostat plus lenalidomide/rituximab versus ...

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with follicular lymphoma and epithelioid sarcoma.

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

PARIS, FRANCE, 09 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision ...

Canada-based Kainova Therapeutics has reported positive top line results from the Phase I EPRAD study of DT-9081, an oral EP4 ...

Pediatric sarcomas are a significant category within pediatric malignancies, comprising over 20% of solid malignant cancers in children. These cancers are ...

Researchers at the Institute of Cytology of the Russian Academy of Sciences have developed an experimental approach to cancer ...